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The effect of atrial pacing on intracoronary thrombox-
ane production was investigated in 35 patients with sta-
ble (n = 19) or unstable (n = 16) angina. Arterial and
coronary sinus thromboxane B2 , the stable metabolite
of thromboxane A2 , myocardial lactate extraction and
thermodilution coronary sinus flow were measured be-
fore, during and immediately after atrial pacing until
the onset of angina. Pacing did not significantlyincrease
coronary sinus thromboxane B2 (rest, 233 ± 107 pg/ml;
pacing, 249 ± 154 pg/ml; postpacing, 330 ± 309 pg/ml)
(mean ± standard deviation) despite a moderate in-
crease in arterial thromboxane B2 (rest, 270 ± 170 pg/
ml; pacing, 387 ± 364 pg/ml; postpacing, 446 ± 420 pg/
ml) (all changes probability [p] < 0.05). A positivetrans-
myocardial thromboxane B2 gradient, suggesting intra-
coronary thromboxane A2 production, occurred in only
five patients at rest (gradient = 60 ± 35 pg/ml). During
pacing, a transmyocardial thromboxane B2 gradient was
Thromboxane Az is an arachidonic acid metabolite produced
by activated platelets that cause marked vasoconstriction of
isolated coronary arteries (1-3) and myocardial ischemia
(4-8) in experimental animals. Several recent studies (9-
11) have demonstrated detectable circulating levels of
thromboxane Bz, the stable metabolite of thromboxane Az,
in patients with coronary artery disease both at rest (12-16)
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not observed despite myocardial lactate production in
18 patients. A postpacing gradient was observed in eight
patients (gradient =284 ± 349 pg/ml). These gradients
weresignificantly more frequent in patients who produced
lactate during pacing (7 of 18) than in patients without
lactate production (l of 17) (p < 0.05). In patients with
and without a postpacing gradient, coronary vascular
resistance decreased with pacing and returned to rest
levels immediately after pacing, suggesting that a post-
pacing thromboxane gradient does not significantlyalter
coronary tone.
These data suggest that: 1) pacing-induced angina is
usually not associated with substantial intracoronary
thromboxane A2 production; 2) in a minority of patients
whodevelop intracoronary thromboxane A2 production,
the amount is small and does not produce significant
coronary vasoconstriction.
and during stress-induced angina (14-17). A positive trans-
myocardial thromboxane Bz gradient, suggesting intracor-
onary thromboxane Az production, has also been noted in
some patients with coronary artery disease (12,14,16,17).
Consequently, it has been postulated that intracoronary
thromboxane Az production plays a role in the pathophys-
iology of angina pectoris. This study was undertaken to
investigate this possibility by evaluating 1) the incidence of
thromboxane Az production in the coronary and noncoro-
nary circulations during pacing-induced angina; 2) the rela-
tion of thromboxane production to myocardial ischemia and
the clinical pattern of angina; and 3) the relation of pacing-
induced thromboxane production to changes in coronary
hemodynamics,
Methods
Patient selection. Thirty-five patients (31 men and 4
women) with coronary artery disease undergoing cardiac
catheterization for evaluation of chest pain were studied.
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The mean age was 55 ± 8 years. Nineteen patients had
stable exertional angina without a change in their clinical
status in the preceding month. Sixteen patients had unstable
angina as defined by a recent change in anginal symptoms
and at least one episode of rest pain in the preceding month.
Seven of these patients had angina at rest associated with
transient ST segment changes within 48 hours of catheter-
ization; none experienced rest angina during the study. All
of the patients had 75% or greater stenosis of one or both
major vessels of the left coronary system and were receiving
long-acting nitrates, or beta-adrenergic blocking agents, or
a combination of both. These medications were withheld for
12 hours before the study. Patients were excluded if they
had been treated with aspirin, dipyridamole or aspirin-con-
taining compounds within 1 week of catheterization. The
study was approved by our institution's Committee for Re-
search Involving Human Subjects and written informed con-
sent was obtained from each patient.
Catheterization protocol. Patients came to the cardiac
catheterization laboratory in the postabsorptive state. A ther-
modilution coronary sinus catheter (Wilton-Webster) was
inserted through the right basilic vein and advanced into the
midcoronary sinus. Position was confirmed by injection of
5 ml of Renografin-76. The thermodilution catheter was
equipped with an electrode tip for pacing and a lumen through
which blood could be sampled. Arterial blood pressure was
measured continuously by a catheter in the femoral or bra-
chial artery. All six electrocardiographic limb leads and one
or two precordial leads were monitored throughout the study.
Atrial pacing. Duplicate baseline measurements of
coronary sinus flow and arterial pressure were recorded.
Arterial and coronary sinus blood samples for thromboxane
B2 and lactate concentrations were obtained. The heart rate
was then increased by coronary sinus pacing in increments
of 20 beats/min every 2 minutes until the patient experienced
anginal pain or a heart rate of 150 beats/min. At the end of
each pacing period, coronary flow, arterial pressure and
electrocardiograms were recorded. At the peak pacing rate,
repeat arterial and coronary sinus samples for thromboxane
B2 and lactate concentration were obtained. Immediately
after the termination of pacing, additional arterial and coro-
nary sinus samples for thromboxane concentration were ob-
tained. At 1 minute after pacing, coronary flow and arterial
pressure were remeasured. The position of the coronary
sinus flow catheter was checked by fluoroscopy at the time
of each flow measurement to ensure a stable position.
Coronary sinus flow. Coronary sinus flow was deter-
mined using a continuous infusion of room temperature 5%
dextrose in water at a rate of 38 mllmin, as previously
utilized in our laboratory 08,19). Both indicator and di-
lution temperature were measured during infusion. Flow
was calculated using the equation of Ganz et al. (20). Du-
plicate flow measurements varied by less than 10%. Coro-
nary vascular resistance was calculated as mean arterial
pressure divided by coronary sinus flow.
Assays. Thromboxane A2 has a half-life of 30 seconds
in aqueous solution and is rapidly converted to the inactive
metabolite thromboxane B2 (9-11). Thromboxane B2 is me-
tabolized and excreted over a period of hours, and conse-
quently may be used to assess acute changes in thromboxane
A2 production 00,11).
Blood samples for thromboxane B2 concentration were
drawn through catheters and collected in plastic tubes con-
taining 4.5 mM sodium ethylenediaminetatra-acetic acid
(EDTA) and 10 pM indomethacin (in final concentration).
The samples were then centrifuged at 6,000 g at 4°C for 10
minutes. Thromboxane B2 was measured by radioimmu-
noassay using a New England Nuclear Kit. Briefly, 0.1 ml
of the patient's platelet free plasma was mixed with 0.1 ml
of Hj-thromboxane B2 and 0.1 ml of thromboxane B2 an-
tibody and incubated overnight at 4° C. Dextran-coated char-
coal was used to separate bound from free thromboxane B2 ,
and the bound fraction was counted in a liquid scintillation
counter. Standard curves were prepared in buffer and cal-
culations were performed according to the manufacturer's
recommendations. The sensitivity of this assay is 180 pg/
ml (0.5 pmollml), and the coefficient of variation is 10%.
The antibody employed has a low cross-reactivity with other
prostaglandins (PG): 0.2% with PGE2 , less than 0.2% with
PGA2 , less than 0.2% with PGF2a and less than 0.2% with
6-keto PGF 1a . Furthermore, our assay detected suppression
of in vitro thromboxane B2 production by aspirin.
To ensure that our sampling technique did not falsely
elevate thromboxane B2 , we obtained femoral venous sam-
ples in five patients by direct needle stick as well as through
our arterial and coronary sinus catheters. Thromboxane was
undetectable in all samples. Other investigators (21-23)
have also reported that this method of sampling does not
activate platelets or falsely elevate thromboxane B2 levels.
Bloodfor lactate determination was deproteinized in iced
10% perchloric acid and assayed on the same day using a
spectrophotometric technique (Sigma Chemical Company
Kit). Lactate extraction in the myocardial bed was calculated
as aortic - coronary sinus lactate concentration/aortic lactate
concentration.
Statistical analysis. Blood samples containing unde-
tectable levels of thromboxane B2 were arbitrarily assigned
a value of 180 pg/ml. Group concentrations were expressed
as mean values ± standard deviations. Group comparisons
were made utilizing nonparametric methods (Wilcoxon signed
rank and Mann-Whitney tests) for paired and nonpaired
data, as appropriate. A probability (p) value less than 0.05
was considered significant.
Results
Atrial pacing increased the heart rate from 64 ± 10 to
123 ± 15 beats/min and the rate-pressure product from
8,750 ± 1,800 to 17,850 ± 2,500 mm Hg beats/min.
Angina developed in 29 of the 35 patients.
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further to 446 ± 420 pg/ml (p < 0.01 compared with base) ,
whereas coronary sinus thromboxane remained unchanged
from basal values (330 ± 309 pg/ml). Eight (23%) of the
35 patients developed a positive transmyocardial throm-
boxane gradient with a mean postpacing coronary sinus
thromboxane level of 510 ± 368 pg/ml (range, 210 to
1,170). Only one of these eight patients exhibited a rest
gradient. The mean gradient (284 ± 349 pg/ml ; range , 30
to 990) was significantly larger than those noted at rest (p
< 0.05) but exceeded 100 pg/ml in only four patients.
Eighteen patients had a higher arterial than coronary sinus
concentration, suggesting noncoronary thromboxane pro-
duction after pacing.
Thromboxane and lactate. During pacing, myocardial
lactate production developed in 18 patients (lactate extrac-
tion: base, 10 ± 24%; pacing , - 25 ± 14%), whereas
lactate extraction was noted in the other 17 patients (lactate
extraction: base, 27 ± 10%; pacing , 16 ± 10%). A post-
pacing positive transmyocardial thromboxane gradient de-
veloped significantly more frequently in the 18 patients who
produced lactate during pacing (7 of 18 patients) than in the
17 patients without lactate production (1 of 17 patients) (p
< 0.05) . In addition, the mean transmyocardial thrombox-
ane gradient postpacing was significantly higher (p < 0.05)
in the patients who developed lactate production than in
patients without lactate production (Table I) .
Thromboxane and anginal pattern. Nineteen patients
had stable angina and 16 patients had unstable angina. In
these two groups, a positive transmyocardial thromboxane
gradient occurred with equal frequency both at rest (stable
group, 3 of 19 versus unstable group, 2 of 16; P = not
significant [NS]) and after pacing (stable group, 4 of 19
versus unstable group, 4 of 16; P = NS). There was no
*
<180
Figure 2. Effect of pacing on transmyocardial arterial-coronary
0 sinus (AO-CS) thromboxane gradients. Patients who developed a
BASE PA CE POST-PACE
positive transmyocardial gradient after pacing are indicated by
broken lines.
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Thromboxane measurements during pacing (Fig. 1
and 2). At rest, 17 (49%) of the 35 patients had detectable
levels of thromboxane B2 in arterial or coronary sinus blood,
or both; mean arterial thromboxane was 270 ± 170 pg/ml
and mean coronary sinus thromboxane was 233 ± 107 pg/
ml. Five patients exhibited a small positive transmyocardial
thromboxane gradient (60 ± 35 pglml; range , 40 to 120),
suggesting intracoronary thromboxane production. Nine pa-
tients had a higher arterial concentration than coronary sinus
concentration.
Pacing increased arterial thromboxane to 387 ± 364 pg/
ml (p < 0.05 compared with base) but did not increase
coronary sinus thromboxane (249 ± 154 pg/ml). No patient
exhibited a positive transmyocardial thromboxane gradient
during pacing.
Immediately after pacing , arterial thromboxane increased
Figure 1. Effect of pacing on arterial (AO) (A) and coronary sinus
(CS) (B) thromboxane 8 2 concentrations . Patients who developed
a positive transmyocardial gradient after pacing are indicated by
broken lines . The number of patients with undetectable throm-
boxane 8 2 at each stage of pacing is indicated. *p < 0.05 versus
base.
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Table 1. Comparison of Thromboxane Bz Concentrations (pg/m!) in Patients Who Developed Myocardial Lactate Production
(n = 18) Versus Patients Who Continued to Extract Lactate (n = 17) During Pacing
Lactate production
Base
Pacing
Postpacing
Lactate extraction
Base
Pacing
Postpacing
AO
292 ± 387
347 ± 478
368 ± 300
251 ± 138
436 ± 473
528 ± 515
CS
256 ± 174
277 ± 349
389 ± 351
209 ± 66
219 ± 105
267 ± 252
Transmyocardial
Gradient (CS-AO)
-36 ± 170
-97 ± 169
22 ± 409*
-42 ± 103
-224 ± 455
-262 ± 409
CS > AO
3 of 18
oof 18
7 of 18*
2 of 17
oof 17
I of 17
*p < 0.05 comparedwith patients with lactate extraction during pacing
AO = artenal, CS = coronary smus.
Table 2. Comparison of Thromboxane Bz Concentrations (pg/
ml) and the Incidence of Positive Transmyocardial Gradients
(CS > AO) in Patients With Stable or Unstable Angina*
difference between the two groups in the absolute arterial
and coronary sinus thromboxane levels noted at rest, during
pacing or after pacing (Table 2).
Seven of the 16 patients with unstable angina developed
angina at rest associated with transient ST segment changes
within 48 hours of catheterization. None of these patients
exhibited a rest or postpacing positive transmyocardial
thromboxane gradient. In addition, their absolute arterial
and coronary sinus thromboxane concentrations throughout
the study were comparable with those of patients with stable
angina.
Thromboxane and coronary hemodynamics. To in-
vestigate the effect of pacing-induced thromboxane pro-
duction on coronary vascular resistance, rest and postpacing
coronary resistance were compared in three groups of pa-
tients: 1) patients with a postpacing positive transmyocardial
thromboxane gradient (n = 8); 2) patients with detectable
thromboxane in arterial or coronary sinus blood, or both,
but without postpacing gradients (n = 18); and 3) patients
with undetectable arterial and coronary sinus thromboxane
levels throughout the study (n = 9). In all three groups,
coronary resistance decreased with pacing and immediately
returned to rest levels after the termination of pacing (Table
*There was no sigmficantdifferencebetweenthe two groups.
AO = arterial, CS = coronary sinus
Stable angina
(19 patients)
Base
Pacing
Postpacing
Unstable angina
(16 patients)
Base
Pacing
Postpacing
AO
278 ± 157
419 ± 406
365 ± 289
268 ± 187
349 ± 317
542 ± 531
CS
248 ± 123
263 ± 180
369 ± 348
221 ± 89
233 ± 119
283 ± 258
CS > AO
3 of 19
o
4 of 19
2 of 16
o
4 of 16
3). Coronary sinus blood flow after pacing did not decrease
below rest levels in any of these groups.
Thromboxane and angina duration. Pacing produced
angina in all 8 patients with a postpacing transmyocardial
thromboxane gradient and also in 21 other patients. Angina
abated spontaneously within 2 minutes after pacing in 7 of
the 8 patients with a thromboxane gradient in contrast to
14 of the 21 patients without a gradient (p = NS).
Discussion
Thromboxane A2 is an arachidonic acid metabolite that
is synthesized by activated platelets (1), and has been de-
tected in the coronary circulation of experimental animals
during ischemia (7,24). Several observations suggest this
prostanoid can exacerbate ischemia: 1) It produces vaso-
constriction in isolated coronary arteries (1-3). 2) Admin-
istration of microsomal incubates containing thromboxane
A2 to guinea pigs and rabbits produces myocardial ischemia,
subendocardial necrosis and occasionally ventricular fibril-
lation (4-6). 3) Blockade of thromboxane activity with pin-
ane thromboxane A2 reduces myocardial ischemia in dogs
(25). Consequently, it has been postulated that the intra-
coronary production of thromboxane Az plays a role in the
pathophysiology of stress-induced myocardial ischemia in
human beings. Accordingly, we examined the incidence and
degree of intracoronary thromboxane production during pac-
ing-induced ischemia in patients with coronary artery disease.
Thromboxane during pacing. Substantial intracoro-
nary production of thromboxane A2 in ischemic myocardium
would be expected to produce a positive transmyocardial
gradient. In the present study, however, we observed small
positive thromboxane gradients in five patients at rest and
these gradients were not associated with lactate production.
During pacing, none of the patients had a positive trans-
myocardial thromboxane gradient, and only eight exhibited
a coronary sinus thromboxane level greater than 200 pg/ml.
Eighteen patients exhibited myocardial lactate production.
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Table 3. Relation of Postpacing Thromboxane 8 2 Concentrations (pg/ml) to Changes in Coronary Vascular Resistance (mm Hgi
ml-rnin - I) During and After Pacing
Postpacing
Thromboxane B2
Undetectable (n = 9)
AO > CS (n = 18)
CS > AO (n = 8)
Postpacing CS
Thromboxane 8 2
< 180
329 ± 327
510 ± 368*
Base
1.4 ± 0.6
1.3 ± 0.6
1.2 ± 0.5
Coronary Vascular Resistance
Pacing
1.0 ± 0.6
0.9 ± 0.4
0.7 ± 0.2
Postpacmg
1.5 ± 0.7
1.2 ± 0.6
1.2 ± 0 .5
*p < 0 .05 compared with pauent s without gradients.
AO = arterial; CS = coronary sinus
Thus , blood samples in these patients were clearly obtained
from ischemic myocardium. These data, therefore, suggest
that extensive intracoronary thromboxane production did not
occur during pacing-induced ischemia, although production
of small amounts of thromboxane A2 in some regions could
not be excluded.
After termination of pacing, a positive transmyocardial
thromboxane gradient was noted in eight patients , but the
gradient was greater than 200 pg/ml in only four. The de-
velopment of a transmyocardial gradient after pacing was
related significantly to the development of myocardial lac-
tate production during pacing , suggesting that thromboxane
production occurs predominantly in ischemic myocardial
beds . These postpacing gradient s may have been due to
small amounts of thromboxane A2 production during pacing
that were not detected until after pacing . Such delayed de-
tection may occur because of a relative reduction of blood
flow to the ischemic areas during pacing . Alternativel y,
thromboxane A2 production may not occur until after the
termination of pacing and may be caused by release of
ischemic byproducts, mechanical events or other factors.
Although substantial intracoronary thromboxane produc-
tion did not appear to occur during pacing, increases in
arterial thromboxane were noted. This observation suggests
that thromboxane production in the noncoronary circulation
frequently occurs during pacing-induced angina. Several
other studies (17 ,27 ,28) have also demonstrated a greater
increase in arterial than in coronary sinus thromboxane lev-
els during pacing. The source of this production is presently
unclear , although platelet activation in the pulmonary or
noncoronary systemic beds is possible .
Relation of thromboxane to coronary hemody-
namics. The presence of intracoronary thromboxane pro-
duction after pacing did not appear to be associated with
substantial coronary vasocon striction . Coronary resistance
decreased during pacing and returned to rest levels after
pacing in patients with and without a postpacing throm-
boxane gradient. In addition, angina was rapidly relieved
by the termination of pacing. Previous studies (19,26) have
demonstrated that thermodilution measurement of coronary
sinus flow can detect changes in coronary resistance produced
by the cold pressor test and by coronary spasm. Therefore,
if persistent extensive changes in coronary resistance oc-
curred in myocardial beds producing thromboxane, it is
likely that they would have been detected.
Because thromboxane A2 has a short half-life, it is un-
certain if thromboxane production in noncoronary vascular
beds can affect coronary tone. The patients in this study
with arterial thromboxane concentrations higher than coro-
nary sinus concentrations after pacing had no detectable
adverse coronary hemodynamic effects . After the termi-
nation of pacing, they had a prompt return of coronary
vascular resistance to rest levels, as did patients without
detectable circulating thromboxane .
Comparison with previous studies. Our observations
that positive transmyocardial thromboxane gradients did not
occur during pacing but developed in some patients im-
mediately after pacing are, in general , compatible with those
of Lewy et al. (17). In a group of 14 patients with coronary
disease , they observed a positive transmyocardial throm-
boxane gradient in only 4 patients during pacing as opposed
to 9 patients after pacing. In addition, Lewy et al. (17) and
others (27 ,28) observed a greater increase in arterial than
in coronary sinus thromboxane levels during pacing, as in
our study. However, our findings suggest that the incidence
of positive postpacing gradients may be less frequent than
that noted in the study of Lewy et al. (17).
Our findings and those of Lewy et al. (17) differ from
the findings of Tada et al. (16). These investigators noted
intracoronary thromboxane production during pacing in 9
of )0 patients with stable exertional angina ; an increase in
arterial thromboxane concentrations was not observed. Dif-
ferences in the patient population , particularly with regard
to the extent of coronary and noncoronary vascular disease
as well as pulmonary disease, may account for these
descrepancies.
Our findings also differ from the observations of Hirsh
et al. (12) concerning the relation of thromboxane produc-
tion to anginal pattern . These investigators noted that rest
transmyocardial thromboxane gradients were frequent in pa-
tients with both unstable angina and pain within 48 hours.
In a preliminary study (14) , they also reported that patients
with unstable angina develop transmyocardial thromboxane
gradients during stress whereas patients with exertional an-
gina do not. Seven patients in our study developed angina
at rest associated with transient ST segment changes within
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48 hours of catheterization. None of these patients had rest
transmyocardial gradients. We also observed no relation
between anginal pattern and stress-induced thromboxane
production. Variation in the extent of coronary disease and
the different types of stress employed by Hirsh et al. (12)
may in part explain these discrepancies.
The studies of Tada et al. (16) and Hirsh et al.(12) also
differ from both the present study and the study of Lewy
et al. (17) with respect to assay techniques. These groups
of investigators increased the sensitivity of their assay by
extracting and concentrating thromboxanes before analysis.
However, this alone cannot account for the differences in
results because the thromboxane levels reported by Tada et
al. (16) and Hirsh et al. (12) were within the range detectable
by our assay.
Clinical implications. This study suggests that pacing-
induced myocardial ischemia is not associated with sub-
stantial intracoronary thromboxane production in the ma-
jority of patients with coronary artery disease. Even in pa-
tients with intracoronary thromboxane production, the
transmyocardial concentration gradients were usually low
and no evidence of major coronary vasoconstriction was
noted. These observations suggest that intracoronary throm-
boxane production may not playa major role in the patho-
genesis of stress-induced angina. This is consistent with
recent observations (27,29) that specific thromboxane in-
hibitors have no significant effect on coronary flow or on
the anginal threshold of patients with coronary disease.
Nevertheless, our data and those of others (14,16,17)
demonstrate that intracoronary thromboxane production oc-
curs in some patients with stress-induced ischemia, and may
indicate an increased propensity for intracoronary platelet
activation and thrombosis. Therefore, it is of interest to
determine whether patients with stress-induced intracoro-
nary thromboxane production have a more malignant clin-
ical course than patients without such production and whether
agents that inhibit thromboxane synthesis are useful in the
treatment of these patients.
We acknowledge the assistance of Nancy L. Shade in the preparation of
this manuscript and the support provided by nursing and technical staff of
the cardiac catheterization laboratory.
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